Literature DB >> 20861098

Is it time to revisit orphan drug policies?

Christopher McCabe, Tania Stafinski, Devidas Menon.   

Abstract

Mesh:

Year:  2010        PMID: 20861098     DOI: 10.1136/bmj.c4777

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  12 in total

1.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 2.  Orphan drugs policies: a suitable case for treatment.

Authors:  Michael Drummond; Adrian Towse
Journal:  Eur J Health Econ       Date:  2014-05

Review 3.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 4.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

5.  The legal imperative for treating rare disorders.

Authors:  Hanna I Hyry; Jonathan C P Roos; Jeremy Manuel; Timothy M Cox
Journal:  Orphanet J Rare Dis       Date:  2013-09-06       Impact factor: 4.123

6.  Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.

Authors:  Mike Paulden; Tania Stafinski; Devidas Menon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

7.  Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.

Authors:  Andrea Messori
Journal:  Sci Pharm       Date:  2016-01-24

8.  Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey.

Authors:  Jeff Richardson; Angelo Iezzi; Gang Chen; Aimee Maxwell
Journal:  Pharmacoecon Open       Date:  2017-03

9.  Sustainable rare diseases business and drug access: no time for misconceptions.

Authors:  Pierrick Rollet; Adrien Lemoine; Marc Dunoyer
Journal:  Orphanet J Rare Dis       Date:  2013-07-23       Impact factor: 4.123

10.  Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach.

Authors:  Garret Kent Fellows; Aidan Hollis
Journal:  Orphanet J Rare Dis       Date:  2013-11-16       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.